12 Apr 2019
A study, published in the British Journal of Pharmacology, indicates a new molecule, which promotes the production of the FGF21 hormone, has anti-diabetic and anti-obesogenic effects that may be useful in developing treatments for non-alcoholic fatty liver disease and diabetes.
Migraines and menopause symptoms linked to cardiovascular disease risk
19 Apr 2024
Risk of postpartum depression associated with stress during adolescence
19 Apr 2024
Surgery for hypoparathyroidism sees reduced facture rates
19 Apr 2024
Patients with type 2 diabetes taking antidepressants have a higher mortality risk
19 Apr 2024